U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H23N3O2S
Molecular Weight 393.5038
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CJ-13610

SMILES

Cc1nccn1-c2ccc(cc2)Sc3cccc(c3)C4(CCOCC4)C(=N)O

InChI

InChIKey=VPTONMHDLLMOOV-UHFFFAOYSA-N
InChI=1S/C22H23N3O2S/c1-16-24-11-12-25(16)18-5-7-19(8-6-18)28-20-4-2-3-17(15-20)22(21(23)26)9-13-27-14-10-22/h2-8,11-12,15H,9-10,13-14H2,1H3,(H2,23,26)

HIDE SMILES / InChI

Molecular Formula C22H23N3O2S
Molecular Weight 393.5038
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

4-(3-((4-(2-Methyl-1H-Imidaz-1-yl)Phenyl)Sulfanyl)Phenyl)Tetrahydro-2H-Pyran-4-Carboxamide, better known as CJ13610, is an orally active inhibitor of 5-lipoxygenase. Originally discovered by deCode Genetics, and later developed by Pfizer, CJ13610 has shown promise in preclinical models for pain. The compound was investigated in phase II clinical trials for asthma and chronic obstructive pulmonary disease; however, these efforts have been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P09917
Gene ID: 240
Gene Symbol: ALOX5
Target Organism: Homo sapiens (Human)
0.569999999999999951 µM [IC50]
Conditions
PubMed

PubMed

TitleDatePubMed
Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.
2004 Jul
In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase.
2010 Jul
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: the referenced study was conducted in rat
Male Sprague-Dawley rats were induced to inflammatory paw pain by subcutaneous injection of a 0.1 mL 1% suspension of carrageenan in saline. Prophylactic treatment with CJ-13610 (1 h before carrageenan) dose-dependently reversed mechanical hyperalgesia by 38 + 7%, 46 + 3% and 90 + 4% with 1, 10 and 30 mg/kg respectively. The CJ-13610 dose was delivered as a 1 mL oral gavage in a vehicle containing 0.5% methylcellulose and 0.025% Tween-20.
Route of Administration: Oral
Human blood was collected in 10 mL heparinized tubes and pooled and dispensed into 384 well experimental plates. Varying concentrations of CJ13610 were dissolved in DMSO, and 2 micro-L was added to each well. CJ13610 was preincubated with blood at room temperature for 10 minutes, followed by stimulation with 40 micro-M calcium ionophore and 30 micro-M arachidonic acid dissolved in 60% ethanol (intended to stimulate maximum leukotriene production). After 15 minute incubation at 37 deg-C blood was centrifuged and leukotriene levels measured from the supernatant. CJ13610 was found to have an IC50 of 0.57 micro-M against the production of leukotrienes.
Substance Class Chemical
Created
by admin
on Sat Jun 26 01:27:16 UTC 2021
Edited
by admin
on Sat Jun 26 01:27:16 UTC 2021
Record UNII
5275PJ1C59
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CJ-13610
Code English
2H-PYRAN-4-CARBOXAMIDE, TETRAHYDRO-4-(3-((4-(2-METHYL-1H-IMIDAZOL-1-YL)PHENYL)THIO)PHENYL)-
Systematic Name English
4-(3-((4-(2-METHYL-1H-IMIDAZOL-1-YL)PHENYL)SULFANYL)PHENYL)TETRAHYDRO-2H-PYRAN-4-CARBOXAMIDE
Systematic Name English
Code System Code Type Description
FDA UNII
5275PJ1C59
Created by admin on Sat Jun 26 01:27:16 UTC 2021 , Edited by admin on Sat Jun 26 01:27:16 UTC 2021
PRIMARY
PUBCHEM
9821945
Created by admin on Sat Jun 26 01:27:16 UTC 2021 , Edited by admin on Sat Jun 26 01:27:16 UTC 2021
PRIMARY
CAS
179420-17-8
Created by admin on Sat Jun 26 01:27:16 UTC 2021 , Edited by admin on Sat Jun 26 01:27:16 UTC 2021
PRIMARY
EPA CompTox
179420-17-8
Created by admin on Sat Jun 26 01:27:16 UTC 2021 , Edited by admin on Sat Jun 26 01:27:16 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
REVERSIBLE
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
IN VITRO
METABOLITE -> PARENT
INN VITRO
METABOLITE -> PARENT
IN VITRO
METABOLITE -> PARENT
IN VITRO
METABOLITE -> PARENT
IN VITRO
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC IN HEALTHY FASTED MALE SUBJECTS

ORAL ADMINISTRATION

SINGLE DOSE

Tmax PHARMACOKINETIC IN HEALTHY FASTED MALE SUBJECTS

ORAL ADMINISTRATION

SINGLE DOSE

Biological Half-life PHARMACOKINETIC SINGLE DOSE

ORAL ADMINISTRATION

IN HEALTHY FASTED MALE SUBJECTS

Tmax PHARMACOKINETIC SINGLE DOSE

ORAL ADMINISTRATION

IN HEALTHY FASTED MALE SUBJECTS